Disease · MONDO_0005055
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| BV+ART vs PTX+ART: Number of Participants With Objective Response for BV+ART vs. PTX+ART | 80 of 132 | 91 of 138 | 270 | NCT01435018 | Trial comparisons |
| BV+ART vs PTX+ART: Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART | 2 of 132 | 0 of 138 | 270 | NCT01435018 | Trial comparisons |
| Arm A: ART Alone or With Delayed ET vs Arm B: ART With Immediate ET: Number of Participants With Grade 3 or Higher Adverse Events | 47 of 94 | 42 of 96 | 190 | NCT01352117 | Trial comparisons |
| Arm A: ART Alone or With Delayed ET vs Arm B: ART With Immediate ET: deaths from any cause | 15 of 94 | 16 of 96 | 190 | NCT01352117 | Trial comparisons |
| Arm A: ART Alone or With Delayed ET vs Arm B: ART With Immediate ET: serious adverse events | 34 of 94 | 34 of 96 | 190 | NCT01352117 | Trial comparisons |
| ET+ART vs PTX+ART: Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART | 6 of 59 | 0 of 59 | 118 | NCT01435018 | Trial comparisons |
| ET+ART vs PTX+ART: Number of Participants With Objective Response for ET+ART vs. PTX+ART | 18 of 59 | 34 of 59 | 118 | NCT01435018 | Trial comparisons |
| High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate) vs Standard Dose Treatment (Nelfinavir Mesylate): deaths from any cause | 0 of 31 | 0 of 36 | 67 | NCT03077451 | Trial comparisons |
| High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate) vs Standard Dose Treatment (Nelfinavir Mesylate): serious adverse events | 1 of 31 | 0 of 36 | 67 | NCT03077451 | Trial comparisons |
| Valganciclovir vs Antiretroviral Combinations: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) | 0 of 20 | 3 of 20 | 40 | NCT03296553 | Trial comparisons |
| Valganciclovir vs Antiretroviral Combinations: deaths from any cause | 3 of 18 | 3 of 19 | 37 | NCT03296553 | Trial comparisons |
| Valganciclovir vs Antiretroviral Combinations: serious adverse events | 0 of 18 | 0 of 19 | 37 | NCT03296553 | Trial comparisons |
| KS; Classic or HIV+ Not Improved on Antivirals vs All Other Advanced HIV-associated Kaposi's Sarcoma (KS): Count of Participants With Serious and Non-serious Adverse Events | 10 of 10 | 6 of 6 | 16 | NCT00923936 | Trial comparisons |
| KS; Classic or HIV+ Not Improved on Antivirals vs All Other Advanced HIV-associated Kaposi's Sarcoma (KS): deaths from any cause | 0 of 10 | 0 of 6 | 16 | NCT00923936 | Trial comparisons |
| KS; Classic or HIV+ Not Improved on Antivirals vs All Other Advanced HIV-associated Kaposi's Sarcoma (KS): serious adverse events | 0 of 10 | 1 of 6 | 16 | NCT00923936 | Trial comparisons |
| HAART vs HAART+ Bevacizumab Injection: Number of Participants With Complete Response | 1 of 7 | 3 of 7 | 14 | NCT01296815 | Trial comparisons |
| HAART vs HAART+ Bevacizumab Injection: serious adverse events | 0 of 7 | 1 of 7 | 14 | NCT01296815 | Trial comparisons |
| NT-I7 (Efineptakin Alfa) Dose Level 1 vs NT-I7 (Efineptakin Alfa) Dose Level 2: deaths from any cause | 0 of 6 | 0 of 2 | 8 | NCT04893018 | Trial comparisons |
| NT-I7 (Efineptakin Alfa) Dose Level 1 vs NT-I7 (Efineptakin Alfa) Dose Level 2: serious adverse events | 1 of 6 | 1 of 2 | 8 | NCT04893018 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005055/comparisons